Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523663 · ClinicalTrials.gov registry record
System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2
A clinical trial, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- 46
- Enrollment target
NCT03523663: Clinical Trial study, sponsored by University of Wisconsin, Madison.
NCT03523663 is a clinical trial that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03523663 was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- 46 participants
- Enrollment target
Study Summary
The goal of this study is to create a formal, quantitative methodology to determine what is the most beneficial dose of Central Nervous System (CNS) stimulant (Ritalin, methylphenidate) to improve cognitive and behavioral function of children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) individually. If successful, it will change the way in which the dose of CNS stimulant for treating ADHD is determined for children in need of therapeutic intervention. The project will be focused on developing the necessary methodology to analyze the children's data with the drift-decision model (DDM), and to develop the required technology, i.e., a computer game with which to measure cognitive/behavioral function and its validation with eye-tracking measurements.
Primary Outcome
Subjects will perform different cognitive tasks and we will record their choices.
Interventions
- OTHER no intervention. measure eye movement data
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-09-11 |
Why NCT03523663 stopped before completion
NCT03523663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which no intervention. measure eye movement data is the first listed.
NCT03523663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03523663 about?
NCT03523663 is a clinical study titled "System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2". The goal of this study is to create a formal, quantitative methodology to determine what is the most beneficial dose of Central Nervous System (CNS) stimulant (Ritalin, methylphenidate) to improve cognitive and behavioral function of children diagnosed with Attention Deficit Hyperactivity Disorder (...
What is the current status of trial NCT03523663?
This trial is currently terminated. The enrollment target is 46 participants. The study started on 2016-01. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT03523663?
The interventions under investigation include: no intervention. measure eye movement data (OTHER).
Who is sponsoring clinical trial NCT03523663?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia